Claudio Laudani Compares Aspirin and P2Y12 Inhibitor Monotherapy in ACS Patients After PCI
Claudio Laudani, Cardiovascular Disease Fellow UNICT, Post-Doc Research Scholar UFHealth JAX, shared a post on LinkedIn:
“Aspirin: another nail in the coffin? (For ACS)
In this systematic review and meta-analysis, we compared the relative benefits of aspirin and P2Y12 inhibitor monotherapy after a short DAPT in ACS patients undergoing PCI.
At interaction analysis, the benefits of short DAPT compared to standard DAPT appear to be driven by P2Y12 inhibitor monotherapy, rather than aspirin monotherapy.
Indeed, P2Y12 inhibitor monotherapy reduced NACE, any bleeding and major bleeding, while aspirin monotherapy retrieved neutral results.
At indirect comparison through network meta-analysis, P2Y12 inhibitor monotherapy reduced NACE by 23% and any bleeding by 32% compared to aspirin monotherapy.
Finally, more robust and high quality evidence exist for P2Y12 inhibitor monotherapy, especially ticagrelor, and our trial sequential analysis reflected this result.”
Read the full article here.
Article: Aspirin or P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention for Acute Coronary Syndromes
Authors: Claudio Laudani, Daniele Giacoppo, Giovanni Occhipinti, Mattia Galli, Antonio Greco, Marco Spagnolo, Luis Ortega-Paz, Francesco Costa, Dominick J. Angiolillo, Davide Capodanno
Stay updated on all scientific advances in the field with Hemostasis Today.
-
Aug 15, 2025, 23:36Irene M Lang's Editorial on Getting Risk Assessment Right in Acute Pulmonary Embolism
-
Aug 15, 2025, 23:31Richard Buka: Many Improvements Needed in HIT Management
-
Aug 15, 2025, 23:29Cathy Harrison: Launching A Journal Club from EAHAD and WFH
-
Aug 15, 2025, 23:24PERT 2025 Symposium Session XIII: Expert Insights on CTEPH Diagnosis, Surgery and BPA Innovations - Join the Conversation
-
Aug 14, 2025, 23:47World Thrombosis Day: Know your Risk in DVT
-
Aug 15, 2025, 23:35SEC61B Mediated Platelet Hyperactivity in People with Diabetes
-
Aug 15, 2025, 23:32Fibrinogen Concentrate Safely Replaces Cryoprecipitate in Neonatal Cardiac Surgery
-
Aug 15, 2025, 23:31Marc Carrier: Low Awareness of Cancer-Associated Thrombosis Among Canadians
-
Aug 15, 2025, 23:28Michael Makris Questions FVIII Aurora’s Potential to Transform Hemophilia A Gene Therapy
-
Aug 15, 2025, 23:27Blood Platelets Capture Tumor DNA and Fetal DNA — Boosting Early Cancer Detection and Prenatal Screening
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Aug 15, 2025, 23:33Kacper Odziomek Excels in 2 Pharmacology Courses from Harvard Medical School
-
Aug 15, 2025, 03:44Call for Global Action on Bleeding Disorders from Baumann, Christoforou and Klamroth
-
Aug 14, 2025, 02:08Jordan Harry's Conversation on Cancer and Clot Risk with Thrombosis Canada
-
Aug 13, 2025, 15:50Will Parsons Honors National Leaders in Hematology: Drs. Fasipe, Powers and Tubman
-
Aug 13, 2025, 10:25Joshua Muia on His HTRS Leadership Role Impact